🇺🇸 FDA
Patent

US 12123001

Methods of treating liver diseases with phosphodiesterase 3B (PDE3B) inhibitors

granted A61KA61K31/7088A61K31/7105

Quick answer

US patent 12123001 (Methods of treating liver diseases with phosphodiesterase 3B (PDE3B) inhibitors) held by REGENERON PHARMACEUTICALS, INC. expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/7088, A61K31/7105, A61K45/06, A61P